Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Gilead

HCV sales down 66% on the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead
2Q Revenues: $5.6 billion (-21%)
2Q Earnings: $1.8 billion (-41%)
YTD Revenues: $10.7 billion (-21%)
YTD Earnings: $3.4 billion (-42%)
Comments: HIV product sales were $3.7 billion in the quarter up 16%, primarily due to continued uptake of Biktarvy and Descovy, Genvoya, and Odefsey. Chronic hepatitis C (HCV) product sales, which consist of Epclusa, Harvoni, Vosevi, and Sovaldi, were $1.0 billion in the quarter, down 66%. The decline was primarily due to lower sales of Harvoni, Epclusa and Sovaldi across all major markets as a result of increased competition. Yescarta, which was launched in the U.S. in October 2017, generated $68 million in sales during the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters